Spectrum pharmaceuticals inc (SPPI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Revenues (Note 1(b))

0

0

0

146,444

162,556

186,830

155,854

267,707

192,963

74,113

38,025

Operating costs and expenses:
Selling, general and administrative

61,373

62,690

64,759

88,418

88,064

97,412

99,315

89,922

72,197

48,550

33,607

Research and development

79,325

75,157

51,525

59,123

51,073

69,662

46,670

41,560

26,662

57,301

21,058

Amortization of intangible assets

-

-

-

25,900

38,319

24,288

20,074

8,818

3,720

3,720

3,720

Total operating costs and expenses

140,698

137,847

116,284

209,330

205,145

218,399

194,639

186,933

136,417

127,010

66,533

Loss from continuing operations before other expense and income taxes

-140,698

-137,847

-116,284

-62,886

-42,589

-31,569

-38,785

80,774

56,546

-52,897

-28,508

Other (expense) income:
Interest income, net

4,996

-340

-6,798

-9,435

-9,074

-8,584

-2,192

-485

297

-

-

Change in fair value of contingent consideration related to acquisitions

-

-

-

-649

676

987

2,871

-20

-

-

-

Change in fair value of common stock warrant liability

-

-

-

-

-

-

-

-

-3,488

2,731

8,075

Other expense, net

-8,892

9,580

389

887

-1,249

-4,367

1,470

-359

280

1,279

662

Total other expense

-3,896

9,240

-6,409

-9,197

-9,647

-11,964

2,149

-844

-2,911

-

-

Loss from continuing operations before income taxes

-144,594

-128,607

-122,693

-72,083

-52,236

-43,533

-36,636

79,930

53,635

-48,887

-19,771

Benefit for income taxes from continuing operations

-9,208

-1,901

-21,941

-2,313

406

2,186

25,498

-14,271

3,704

43

-421

Loss from continuing operations

-135,386

-126,706

-100,752

-

-

-

-

-

-

-

-

Income from discontinued operations, net of income taxes (Note 10)

22,697

5,965

8,563

-

-

-

-

-

-

-

-

Net loss

-112,689

-120,741

-92,189

-69,770

-52,642

-45,719

-62,134

94,201

-

-48,844

-19,046

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-1,146

Net loss

-

-

-

-

-

-

-

-

49,931

-48,844

-20,192

Loss per common share from continuing operations (in dollar per share)

-1.22

-1.23

-1.18

-

-

-

-

-

-

-

-

Income per common share from discontinued operations (in dollar per share)

0.21

0.06

0.10

-

-

-

-

-

-

-

-

Net loss per common share ($ per share)

-

-

-

-0.96

-0.81

-0.71

-1.02

1.61

0.94

-0.99

-0.48

Earnings Per Share, Diluted

-

-

-

-0.96

-0.81

-0.71

-1.02

1.46

0.86

-0.99

-0.48

Earnings Per Share, Basic and Diluted

-1.02

-1.17

-1.08

-

-

-

-

-

-

-

-

Weighted average shares outstanding:
Basic (shares)

110,585

103,305

85,115

72,824

64,882

64,708

60,729

58,588

53,272

49,502

39,273

Diluted (shares)

110,585

103,305

85,115

72,824

64,882

64,708

60,729

64,637

57,959

49,502

39,273

Product [Member]
Total revenues

-

-

-

128,596

136,851

186,537

143,475

254,992

180,663

60,921

28,225

Cost of sales (excludes amortization of intangible assets)

-

-

-

27,953

27,689

27,037

28,580

46,633

33,838

17,439

8,148

License and Service [Member]
Total revenues

-

-

-

17,848

25,705

293

12,379

12,715

12,300

13,192

9,800

Service [Member]
Cost of Goods and Services Sold

-

-

-

7,890

0

0

-

-

-

-

-